On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Oral Ulcers in Behçet's Disease
Behçet’s Disease, also referred to as Behçet’s Syndrome, is classified as a variable vessel vasculitis.1
References: 1. Leonardo NM, McNeil J. Int J Rheumatol. 2015;2015:945262. 2. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335(8697):1078-1080. 3. Alpsoy E, Donmez L, Onder M, et al. Br J Dermatol. 2007;157(5):901-906. 4. Yazici Y, Yazici H, eds. Behçet’s Syndrome. New York, NY: Springer; 2010:7-34. 5. Zeidan MJ, Saadoun D, Garrido M, et al. Autoimmun Highlights. 2016;7(1):4. 6. Alpsoy E. J Dermatol. 2016;43(6):620-632. 7. Melikoglu M, Melikoglu M. Acta Reumatol Port. 2014;39:46-53. 8. Bang D, Hur W, Lee ES, Lee S. J Dermatol. 1995;22(12):926-929. 9. Ambrose NL, Haskard DO. Nat Rev Rheumatol. 2013;9(2):79-89. 10. Lee S, Bang D, Lee ES, Sohn S, eds. Behçet’s Disease: A Guide to its Clinical Understanding Textbook and Atlas. Heidelberg, Germany: Springer-Verlag; 2001:19-50. 11. Gualtierotti R, Marzano AV, Spadari F, et al. J Clin Med. 2019;8(1):1-19; http://creativecommons.org/licenses/by/4.0/. 12. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.
Otezla® (apremitast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations